Morris, Emma C. http://orcid.org/0000-0003-4834-1130
Neelapu, Sattva S. http://orcid.org/0000-0003-1045-4914
Giavridis, Theodoros http://orcid.org/0000-0002-8716-781X
Sadelain, Michel
Article History
Accepted: 1 April 2021
First Online: 17 May 2021
Competing interests
: M.S. and T.G. are listed as inventors in a Memorial Sloan Kettering-held patent application related to treatment of cytokine release syndrome: ‘Methods and compositions for alleviating cytokine release syndrome’ (WO2019099993A1). E.C.M. is scientific co-founder of Quell Therapeutics Ltd, which is developing chimeric antigen receptor (CAR)-modified regulatory T cells, and has served as a consultant to Kite, a Gilead company. S.S.N. served as consultant to Kite, a Gilead Company, Merck, Bristol-Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr and Unum Therapeutics; received research support from Kite, a Gilead Company, Bristol-Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences and Acerta; received royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy.
Free to read: This content has been made available to all.